Enveric Biosciences is a publicly-traded biotechnology company predominantly focused on leveraging cannabinoids as treatments for cancer and oncology treatment-caused indications. They have recently expanded into the psychedelic space through the acquisition of MagicMed in September 2021.
Enveric Biosciences
Enveric has expanded its drug pipeline to include an extensive library (Psybrary™) of patented novel psychedelic molecules. The company recently announced that it has identified several promising novel candidates from its Psybrary™.
Enveric intends to develop novel psychedelic compounds into therapies for indications such as cancer-related stress and post-traumatic stress disorder (PTSD).
Activities
B2C
Drug Discovery
Compounds of Interest
Psilocybin
DMT
Mescaline
MDMA
Topics of Interest
Anxiety
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders (Press Release, 18 January 2022)In this investor update, Joseph Tucker of Enveric Biosciences shares that the company has raised $25 million in 2021, acquired MagicMed and filed 15 patents.
The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of (Motherboard, 24 January 2022)
This article, by the always excellent Shayla Love, discussed the next generation of novel psychedelics. Starting with the many discoveries of Sasha Shulgin, the article then dives deeper into the wishes and hopes of psychedelic companies.